gp2 peptidegp2 peptide GP2 peptide is under investigation in clinical trial NCT00524277 - skye-peptides-discount-code-first-order-free-shipping GP2 is a HER2-derived, HLA-A2+ restricted peptide The GP2 Peptide: A Deep Dive into its Role in HER2/neu Targeted Therapies

gprp-peptidegprp-peptide The GP2 peptide has emerged as a significant entity in the field of cancer immunology, particularly as a component of therapeutic vaccines targeting the HER2/neu protein. This exploration delves into the scientific underpinnings, clinical applications, and ongoing research surrounding this immunogenic peptide, drawing from extensive scientific literature and clinical trials.

Understanding the GP2 Peptide and its HER2/neu Connection

The GP2 peptide is a precisely defined sequence derived from the transmembrane portion of the HER2/neu protein. HER2/neu (also known as ErbB2) is a receptor tyrosine kinase that plays a crucial role in cell growth and division.A randomized, multicenter, placebo-controlled, phase III ... In certain cancers, particularly a subset of breast cancers, HER2/neu is overexpressed, leading to uncontrolled cell proliferation and a more aggressive disease phenotype. This overexpression makes HER2/neu a prime target for immunotherapies.

Research has shown that GP2 is a clinically relevant HER2/neu-derived peptide. Its significance lies in its ability to elicit an immune response against HER2/neu-expressing cancer cells. Unlike some other HER2-derived peptide vaccines such as AE37, which primarily target a CD4+ T-cell response, GP2 elicits a CD8+ response against the HER2/neu protein.Abstract Background: We have conducted clinical trials of theHER2 peptide GP2(MHC Class I restricted) vaccine in clinically disease-free breast cancer ... This cytotoxic T-lymphocyte (CTL) response is crucial for directly killing cancer cells.

Early research, such as that by Kuhns et al. in 1999, identified that while the specific sequence of the peptide, GP2 (IISAVVGIL), might bind poorly to HLA-A2.1, it possesses anchor residues present in high-affinity peptides, suggesting its potential for immunogenicityKnow about technical details ofGP2 Peptidelike: chemical name, chemistry structure, formulation, uses, toxicity, action, side effects and more at .... Further studies confirmed that GP2 is a HER2-derived, HLA-A2+ restricted peptide, meaning it can be recognized by T-cells of individuals with the HLA-A2+ genetic type.

Clinical Investigations and Applications of GP2 Peptide Vaccines

The development of GP2 peptide-based vaccines has been a focus of numerous clinical trials, aiming to leverage its immunogenic properties for therapeutic benefit. A key aspect highlighted in several studies, including work by Mittendorf et al., is the evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. These investigations have explored different adjuvant combinations to enhance the immune response.

One such promising combination is GP2 + GM-CSF has been shown to be safe and effective in eliciting anti-HER2 immune response in breast cancer patients. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) acts as an adjuvant, stimulating the immune system to better recognize and respond to the GP2 peptide. Initial Phase I studies, as reported by Mittendorf et al. in 2016, demonstrated that GP2 administered with GM-CSF to be safe and immunogenic.

Further research has investigated novel immunotherapy strategies, including the conjugation of GP2 peptide to various delivery systemsEvaluation of the HER2/neu‐derived peptide GP2 for use in a .... For instance, studies on conjugated nanoliposome with the HER2/neu-derived GP2 peptide have shown that co-formulation with components like DOPE and MPL can induce high antitumor immunity and enhance therapeutic outcomes. Similarly, bacteriophage lambda nanoparticles displaying the HER2/neu derived peptide GP2 have been explored as anti-cancer vaccines in preclinical models.

GP2 Peptide: Dosage, Efficacy, and Future Directions

The precise formulation and dosage of GP2 peptide are critical for its efficacy. GP2 is a biologic nine amino acid peptide of the HER2/neu protein delivered in combination with Granulocyte-Macrophage Colony-Stimulating Factor.Oligopeptides: What They Are and Why You Want Them in Your ... The immunogenicity of GP2 has been compared to other HER2-derived peptide vaccines like E75, with some research suggesting that GP2, derived from the transmembrane portion of HER-2/neu, has differing binding characteristics and may be more immunogenic than E75.作者：JJ Kuhns·1999·被引用次数：147—Thispeptide, GP2(IISAVVGIL), binds very poorly to A2 but has anchor residues that are present in high affinitypeptides(Ile at position 2 and Leu at position ...

The GP2 peptide is under investigation in clinical trial NCT00524277 (Vaccine Therapy in Treating Patients With Breast Cancer), indicating ongoing efforts to refine its application. While GP2 are HLA-A2-restricted immunogenic peptides, ongoing research continues to explore its broader applicability and optimization. Studies have demonstrated that GLSI-100, which incorporates the GP2 peptide, safely elicits a potent immune response, evidenced by increased delayed-type hypersensitivity (DTH) skin responses and improved immune markers作者：A Razazan·2019·被引用次数：46—Bacteriophage λ displaying aHER2/neu derived peptide GP2was constructed and used as an anti-cancer vaccine in a BALB/c mouse xenograft tumor ....

The search intent surrounding GP2 peptide reflects a strong interest in its mechanism of action, clinical trials, and its role as a HER2 peptide GP2 vaccine. The exploration of peptides in cancer therapy, and specifically the evaluation of the HER2/neu-derived peptide GP2, underscores the ongoing scientific endeavor to harness the body's own immune system to combat cancer.作者：EA Mittendorf·2016·被引用次数：120—GP2 is a HER2-derived, HLA-A2+ restricted peptide. Phase I studies showed GP2 administered with GM-CSF to be safe and immunogenic. Here we ... Advancements in understanding the interplay between peptides, the immune system, and cancer targets like HER2/neu continue to pave the way for more effective and targeted cancer treatments作者：JJ Kuhns·1999·被引用次数：147—Thispeptide, GP2(IISAVVGIL), binds very poorly to A2 but has anchor residues that are present in high affinitypeptides(Ile at position 2 and Leu at position ....